Merck & Co Inc

NYSE:MRK   11:20:24 AM EDT
80.52
-0.06 (-0.07%)
Products, Regulatory

Merck And Ridgeback's Molnupiravir, Investigational Oral Antiviral COVID-19 Treatment, Receives Special Approval For Emergency In Japan

Published: 12/24/2021 11:58 GMT
Merck & Co Inc (MRK) - Merck and Ridgeback’s Molnupiravir, an Investigational Oral Antiviral Covid-19 Treatment, Receives Special Approval for Emergency in Japan.
Japan's Ministry of Health, Labor and Welfare Approves Molnupiravir for Treatment of Sars-cov-2 Infection.
Under Previously Supply Agreement, Japanese Government Will Purchase 1.6 Million Courses of Molnupiravir to Accelerate Access to Patient.
In Japan, Lagevrio (molnupiravir) is the Planned Trademark for Molnupiravir.